Podcasts

Articles

Webinars

Peer-Reviewed

Videos

AMCP Nexus: The Academy of Managed Care Pharmacy Nexus

The proposal to allow HHS to negotiate Medicare Part D drug prices is relatively realistic although the outcome will vary a lot drug by drug and class by class, said Melissa Andel, MPP, vice president of health policy at CommonHealth Solutions.

Melissa Andel Speculates on Medicare Negotiating Drug Prices With Pharma Companies

The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.

Christina Barrington on the Benefit of RWE for Subpopulations and Diverse Populations

As deductibles for Medicare Part D beneficiaries and enrollment continue to rise, new policies and reconciliation negotiations aimed at lowering costs may hold the key to stabilizing Part D plans, according to presenters at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Panel: New Medicare Part D Policies and Requirements Aim to Lower Plan Costs

Two posters presented at AMCP Nexus 2021 review the high burden of social determinants of health (SDOH) on patients with serious mental illness.

Evaluating the High SDOH Burden for Patients With Serious Mental Illness

During her presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting, Aimee Tharaldson, PhD, highlighted the most anticipated specialty pharmacy drugs awaiting FDA approval, including several treatments for cancer and rare diseases.

Cancer Treatments, Orphan Drugs, Gene Therapies Represent Big Areas to Watch in Specialty Drug Pipeline

Novel financial concepts will help to ensure sustainable access to gene and cell therapies, which may help reduce disparities, said Jane F. Barlow, MD, MPH, MBA, senior advisor, FoCUS Project, MIT Center for Biomedical Innovation, and executive vice president and chief clinical officer at Real Endpoints.

Dr Jane Barlow: Novel Financing Can Improve Access, Remove Barriers to Novel Therapies

There are potential ways that precision medicine could exacerbate disparities, but it should be used to guide people to the right treatments, said Nick Page, chief clinical and strategy officer, and Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, vice president of clinical programs and services, WellDyne.

Dr Patty Taddei-Allen and Nick Page Discuss Precision Medicine and Health Disparities

A panel discussion at AMCP Nexus 2021 explored the current biosimilar landscape and level of uptake, with survey results showing payers are accepting of biosimilars and that a majority support nonmedical switching.

Panel: Biosimilar Acceptance May Be Greater Among Payers Than Previously Thought

A panel of experts highlighted a number of emerging product solutions that can help health plans overcome challenges associated with financing and reimbursing gene and cell therapies and offered insight into how these solutions can be expanded as more therapies enter the market.

Emerging Solutions to Address Financial, Reimbursement Challenges Associated With Gene and Cell Therapies

Multiple trastuzumab biosimilars were approved and launched very quickly in the United States, which sets up an interesting scenario in the market to see the nuance of having multiple options available, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).